Toronto Dominion Bank
SPRY icon

Toronto Dominion Bank’s ARS Pharmaceuticals SPRY Stock Holding History

Toronto Dominion Bank’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-2
Closed – – 1830
2022
Q1 		$0 Hold
2
– – ﹤0.01% 1936
2021
Q4 		$0 Buy
+2
New +$16 ﹤0.01% 1963

Other funds holding SPRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Toronto Dominion Bank's SPRY Position: Q2 2022 in Review

Toronto Dominion Bank sold out of ARS Pharmaceuticals (SPRY) in Q2 2022, closing a stake of 2 shares.

Toronto Dominion Bank first reported a position in SPRY in Q4 2021 and held it in 2 quarters. The position peaked at $0 in Q1 2022. 64 funds tracked by Wall St. Rank hold SPRY as of Q2 2022.

  • Toronto Dominion Bank reported no remaining ARS Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Toronto Dominion Bank sold 2 ARS Pharmaceuticals shares in Q2 2022.
  • Toronto Dominion Bank first reported a position in ARS Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Toronto Dominion Bank's ARS Pharmaceuticals position peaked at $0 in Q1 2022.
  • 64 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2022.

Based on Toronto Dominion Bank's 13F filing for Q2 2022, filed 11 Aug 2022.